Andrea L. Kasinski
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
Publications
113
Citations
3,975
Est. group size
~14
Recurring co-author estimate
Active years
25
Publishing since 2002
Andrea L. Kasinski's lab studies small RNA molecules called microRNAs (short genetic regulators that control which genes are turned on or off) and how they can be harnessed or targeted to treat cancer, particularly lung and breast cancers. Their work spans designing chemically modified microRNA therapeutics (such as miR-34a and miR-362-3p) for improved drug delivery and studying epigenetic regulators like KMT5C, an enzyme that modifies chromatin (the packaging of DNA), in relation to cancer drug resistance. Much of the research combines molecular biology techniques with translational, disease-focused applications, including mouse models of lung cancer and treatment-resistant tumors.
Publication output has grown notably in recent years, rising from a handful of papers annually before 2021 to a peak of 26 in 2023, with continued strong activity (around 12/year) through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 7903: MiR-362-3p enhances platinum response in breast cancer
Cancer Research · 2026
- The miR-362-3p/ <i>BCLAF1</i> axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
medRxiv · 2026
- Insight into the mechanisms and dysregulation of KMT5C-H4K20me3 in cancer
Epigenetics · 2025
- BPS2025 - To the tumor and beyond: Tales of a holistic miRNA delivery vehicle
Biophysical Journal · 2025
- Abstract 2719: Decoding role of KMT5C-H4K20me3 in EGFRi resistance in non-small cell lung cancer
Cancer Research · 2025
- Abstract 2725: Noncanonical regulation of genes by KMT5C-H4K20me3 in EGFR inhibitor resistant non-small cell lung cancer
Cancer Research · 2025
- Abstract 6691: A divalent and chemically modified microRNA-34a with enhanced circulation kinetics and improved endosomal escape for the treatment of triple-negative breast cancer
Cancer Research · 2025
- Abstract 6699: Development of a fully modified miR-34a (FM-miR-34a) cancer therapeutic: a translational research study
Cancer Research · 2025
- Preparing and Evaluating the Stability of Therapeutically Relevant Oligonucleotide Duplexes
BIO-PROTOCOL · 2024
- MicroRNA is the Nobel-winning master regulator of the genome – researchers are learning to treat disease by harnessing how it controls genes
2024
- Abstract PR007: To the tumor and beyond: Tales of a holistic miRNA delivery vehicle
Molecular Cancer Therapeutics · 2024
- MicroRNA, descoberta ganhadora do Nobel de Medicina de 2024, pode curar doenças ao controlar o genoma
2024
- Histone 4 lysine 20 tri-methylation: a key epigenetic regulator in chromatin structure and disease
Frontiers in Genetics · 2023
- Supplementary Figure 1 from miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma
2023
- Supplementary Figure 3 from miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma
2023
- Cancer Research×32
- bioRxiv (Cold Spring Harbor Laboratory)×5
- BIO-PROTOCOL×3
- Molecular Therapy — Nucleic Acids×2
- Scientific Reports×2
- Xinna Zhang
Biochemistry, Genetics and Molecular Biology · Indiana University
- Pierluigi Gasparini
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Paolo Fadda
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Ikjot Singh Sohal
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Giovanni Nigita
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile